Menu
Not yet recruiting NCT07548918

Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo"

Phase II Interventional Vitiligo - Macular Depigmentation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: microneedling with minoxidil 5% and NBUVB, Microneedling with Minoxidil5%.
Who it may be relevant to
Registry conditions: Vitiligo - Macular Depigmentation. Basic parameters: 16 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparative Clinical and Histopathological Study of Microneedling With Topical Minoxidil 5% Versus Microneedling With Topical Minoxidil 5% Combined With Narrow-Band Ultraviolet B Phototherapy in the Treatment of Stable Vitiligo

Overview

This study is a randomized controlled trial comparing microneedling with topical minoxidil 5% versus microneedling with minoxidil combined with NB-UVB phototherapy in stable vitiligo. It aims to evaluate both clinical and histopathological outcomes in 30 patients with non-segmental stable vitiligo. Vitiligo is a chronic depigmenting disorder caused by melanocyte destruction with significant psychosocial impact. The study also investigates immunohistochemical changes, particularly Wnt/β-catenin signaling expression in lesional skin. The combination therapy is expected to enhance repigmentation by improving melanocyte activation, drug delivery, and angiogenesis

Interventions

  • Combination product microneedling with minoxidil 5% and NBUVB
    Micronnedlin depth 1% then topical Minoxidil5% and Narrow Band UVB
  • Combination product Microneedling with Minoxidil5%
    Microneedling with topical Minoxidil 5%

Primary outcome measures

  • Repigmentation in the vitiliginous area after receiving the treatment and increasing the wnt b catenin marker level in the histopathological specimen [Time frame: From enrollment to the end of treatment at 16 weeks for each patient]

Eligibility criteria

Inclusion criteria

  • Patients with stable non-segmental vitiligo
  • No new lesions
  • No enlargement of existing lesions
  • Patients of both sexes
  • Age 16 years or older

Exclusion criteria

  • Active vitiligo
  • Pregnant or lactating women
  • History of keloid formation
  • Hematological disorders
  • Coagulopathies
  • Use of anticoagulant therapy
  • Use of medications that may prolong bleeding
  • Previous vitiligo treatment in the last 2 months

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Factorial
Masking
Double blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Abdelghany, n. i., r. s. abdo and W. M. Abdelmaged (2022). "Microneedling in treatment of vitiligo: a review article." Sohag Medical Journal 26(1): 1-7. Bajoria, S., C. R. Srinivas, N. Satish, R. Sukhija, K. Jain, G. Manocha and L. Besra (2025). "Phototherapy with Topical Minoxidil in Vitiligo: A Randomized Control Trial." Indian Dermatol Online J. Elshafy Khashaba, S. A., R. A. Elkot and A. M. Ib

Identifiers

NCT: NCT07548918 · Soh-Med-26-3-5MS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗